SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Breakthrough Treatment for Treatment-Resistant Depression In a significant development for those living with treatment-resistant depression, the U.S.Food and Drug Administration (FDA) has granted approval for